284 related articles for article (PubMed ID: 16682982)
1. Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy?
Diehl V; Engert A
Nat Clin Pract Oncol; 2006 May; 3(5):227. PubMed ID: 16682982
[No Abstract] [Full Text] [Related]
2. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
3. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
Hehn ST; Miller TP
Curr Hematol Rep; 2004 Jan; 3(1):17-26. PubMed ID: 14695845
[TBL] [Abstract][Full Text] [Related]
4. Hodgkin's disease--clinical trials and travails.
DeVita VT
N Engl J Med; 2003 Jun; 348(24):2375-6. PubMed ID: 12802021
[No Abstract] [Full Text] [Related]
5. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma?
Eichenauer DA; Engert A
Leuk Lymphoma; 2009 Nov; 50(11):1733-4. PubMed ID: 19883301
[No Abstract] [Full Text] [Related]
7. Treatment of advanced stage Hodgkin lymphoma--it's all about risk-benefit.
Phipps C; Lee YS; Hwang W
Br J Haematol; 2012 Oct; 159(1):113-5. PubMed ID: 22823109
[No Abstract] [Full Text] [Related]
8. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy for Hodgkin's disease.
Ekert H
N Engl J Med; 2003 Sep; 349(12):1186-7; author reply 1186-7. PubMed ID: 13679536
[No Abstract] [Full Text] [Related]
10. [Treating Hodgkin's disease: for whom the more means better?].
Illés A
Magy Onkol; 2004; 48(2):157-61. PubMed ID: 15351812
[TBL] [Abstract][Full Text] [Related]
11. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study.
Engert A; Bredenfeld H; Döhner H; Ho AD; Schmitz N; Berger D; Bacon P; Skacel T; Easton V; Diehl V
Haematologica; 2006 Apr; 91(4):546-9. PubMed ID: 16585019
[TBL] [Abstract][Full Text] [Related]
12. Hodgkin lymphoma presenting with hair graying.
Trakymiene SS; Abla O
J Pediatr Hematol Oncol; 2010 Jul; 32(5):417-8. PubMed ID: 20502355
[No Abstract] [Full Text] [Related]
13. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials.
Haverkamp H; Böll B; Eichenauer DA; Sasse S; Fuchs M; Borchmann P; Diehl V; Engert A; von Tresckow B
J Clin Oncol; 2015 Aug; 33(22):2430-6. PubMed ID: 26101245
[TBL] [Abstract][Full Text] [Related]
14. Early treatment intensification with escalated BEACOPP in patients with Hodgkins lymphoma not responding to ABVD therapy.
Danielewicz I; Małkowski B; Zaucha R; Zalewska M; Leśniewski-Kmak K; Zaucha JM
Acta Oncol; 2014 Feb; 53(2):286-8. PubMed ID: 24304391
[No Abstract] [Full Text] [Related]
15. [Role of response to first-line chemotherapy and of the primary lesion in Hodgkin lymphoma].
Datsenko PV; Pan'shin GA; Sotnikov VM; Ivashin AV; Gombolevskiĭ VA; Golub SV; Evstikheev ÉV
Vopr Onkol; 2012; 58(1):66-70. PubMed ID: 22629831
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Hodgkin lymphoma: a 50-year perspective.
Canellos GP; Rosenberg SA; Friedberg JW; Lister TA; Devita VT
J Clin Oncol; 2014 Jan; 32(3):163-8. PubMed ID: 24441526
[No Abstract] [Full Text] [Related]
17. Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
Bauer K; Herbst C; Brillant C; Monsef I; Kluge S; Skoetz N; Engert A
J Natl Cancer Inst; 2010 Jun; 102(12):E1. PubMed ID: 20551424
[TBL] [Abstract][Full Text] [Related]
18. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
[TBL] [Abstract][Full Text] [Related]
19. [The optimal total focal radiotherapy dosage after first-line chemotherapy in patients with Hodgkin lymphoma].
Datsenko PV; Pan'shin GA; Sotnikov VM; Ivashin AV; Evstikheev ÉV; Golub SV; Gombolevskiĭ VA
Vopr Onkol; 2012; 58(4):527-31. PubMed ID: 23607209
[TBL] [Abstract][Full Text] [Related]
20. Fourth biannual report of the Cochrane Haematological Malignancies Group.
Kober T; Hülsewede H; Bohlius J; Engert A
J Natl Cancer Inst; 2006 Apr; 98(8):E1. PubMed ID: 16622111
[No Abstract] [Full Text] [Related]
[Next] [New Search]
